NFE2L2 Antibodies

Nuclear factor erythroid 2-related factor 2 (NFE2L2)

Transcription activator that binds to antioxidant response (ARE) elements in the promoter regions of target genes. Important for the coordinated up-regulation of genes in response to oxidative stress and the regulation of cellular redox conditions.

May be involved in the transcriptional activation of genes of this beta-globin audience by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region. .

Gene Information

Human
Gene Name:	NFE2L2
Uniprot:	Q16236
Entrez:	4780

Family

Belongs to:
bZIP family

Alternative Names

HEBP1; NFE2L2; NF-E2-related factor 2; NFE2-related factor 2; NRF2 erythroid derived 2, like 2; Nrf2 ihc; Nrf2 immunofluorescence; Nrf2 immunohistochemistry; Nrf2 polyclonal; Nrf2 rat; Nrf2 western blot; Nrf2; nuclear factor (erythroid-derived 2)-like 2; nuclear factor erythroid 2-related factor 2; nuclear factor erythroid-derived 2-like 2

Molecular Weight

Mass (kDA):
67.827 kDA

Genomic Context

Human
Location:	2q31.2
Sequence:	2; NC_000002.12 (177230303..177265131, complement)

Tissue Specificity

Widely expressed. Highest expression in adult muscle, kidney, lung, liver and in fetal muscle.

Subcellular Localizations

Cytoplasm, cytosol. Nucleus. Cytosolic under unstressed conditions: ubiquitinated and degraded by the BCR(KEAP1) E3 ubiquitin ligase complex (PubMed:15601839, PubMed:21196497). Translocates into the nucleus upon induction by electrophilic agents that inactivate the BCR(KEAP1) E3 ubiquitin ligase complex (PubMed:21196497).

Diseases

• Malignant Neoplasms
• Inflammation
• Neoplasms
• Carcinogenesis
• Carcinoma
• Neurodegenerative Disorders
• Liver Carcinoma
• Cell Transformation, Neoplastic
• Parkinson Disease
• Lung Diseases
• Lung Neoplasms
• Malignant Neoplasm Of Breast
• Malignant Neoplasm Of Lung

• Injury To Liver
• Diabetes Mellitus
• Adenocarcinoma
• Inflammatory Response
• Nerve Degeneration
• Mammary Neoplasms
• Chronic Obstructive Airway Disease

Interacting Proteins

• ATF4
• KEAP1
• MAFG
• MAFK
• Pml

• RARA
• Rara
• TNNT1
• WAC

Pathways

• Cell Death
• Pathogenesis
• Localization
• Response To Oxidative Stress
• Neuroprotection
• Aging
• Cell Proliferation
• Inflammatory Response
• Cell Growth
• Cell Cycle
• Secretion
• Conjugation
• Transport

• Angiogenesis
• Rna Interference
• Autophagy
• Excretion
• Translation
• Drug Resistance
• Nuclear Export

PTMs

• Phosphorylation
• Ubiquitination
• Oxidation
• Cleavage
• Reduction
• Acetylation
• Methylation

• Nitrosylation
• Deacetylation
• Sumoylation
• Demethylation
• Carboxylation
• Glutathionylation
• Nitration

• Biotinylation

Research Areas

• Transcription Factors and Regulators

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/NFE2L2

Boster Bio: Best Uses Of The NFE2L2 Marker

This article will focus on the Boster Bio: NFE2L2 marker. It discusses the various uses for it as well as what the anti-NFE2L2 marker does. If you're looking for an effective marker that can enable you to identify rare mutations, this article will assist you in making a decision. Find out more about the marker here. Boster Bio: The NFE2L2 marker has a myriad of uses. It is crucial to understand the best way to utilize it.

Boster Bio NFE2L2 Marker

The NFE2L2 is a well-known biological assay. It is present in a wide variety of animal tissues and cells, and boster Bio antibodies are polyclonal or monoclonal. Boster Bio uses mouse and rabbit as models for the development of its antibodies. The NFE2L2 gene may be a transcriptional activator for beta-globin audience gene genes. This could be a result of an enhancer function at the hypersensitive site 2 in the beta-globin locus control.

Applications

The NFE2L2 gene encodes the protein nuclear factor erythroid-derived 2-like 2. It regulates the expression and function of various proteins that include antioxidants and detoxifying enzymes, and enzymes that metabolize drugs. The NFE2L2 protein is primarily stored in the cytoplasm. However, it is transported to and from the nucleus to activate transcription of antioxidative genes. This gene is expressed in tumors, tumor cells and healthy parotid gland tissue.

This gene has polymorphisms that are part of the pyrimidine rich intronic sequence. These polymorphisms impact the splicing the RNA and are associated with diseases. Both c.351T (and c.423G) were identified to be associated with Parkinson's disease in a case-control study that included 210 patients and 148 healthy controls from the Henan province, China. The association results revealed that the two exonic SNPs were related to PD in Chinese populations.

Researchers made use of an antibody to determine NFE2L2's mRNA to test the effects of the drug on the growth of tumors. They also tested the mRNA levels of GSTP1, GSTM1, and HO-1. The NFE2L2 variants decreased the activation of the ARE-induced Firefly Luciferase gene in PBMC cells. Using the NFE2L2 variants as a loading control they found that NFE2L2 significantly reduced the ARE-driven transcription.

Genomic DNA from all subjects was taken for PCR and sequenced. For comparison, the PCR products of interest were analyzed using an Sanger sequencer and the ABI Prism GeneScan and Genotyper software. Primers for the NFE2L2 gene were created according to the genomic sequences from different species and the GenBank DNA database. Then, multiple alignments of sequences were carried out using the Clustal W software.

Despite the promising results of the NFE2L2 gene however, these studies have limitations. There are multiple functional polymorphisms in genes that encode NFE2L2 that can affect the ability of the protein to express PPAR gamma an oxidative stress reaction protein. Additionally the NFE2L2 gene is associated with oxidative stress, which is a hallmark of Parkinson's disease (PD).

The KEAP1/NFE2L2 gene mutations are associated with lower survival outcomes for patients who receive chemotherapy and immunotherapy to treat their NSCLC. The KEAP1/NFE2L2 mutation was present in 118/58 patients. The gene is also expressed in natural Treg cells as well as CD4 T cells, but its expression in these immune cells is not as high. This gene could be a target for immunotherapy and other cancer therapies.

Anti-NFE2L2 marker

Anti-NFE2L2 is a soluble immunoglobulin manufactured by the Boster Bio company. This protein is a member the BTG/TOB gene cluster and has been implicated in the regulation of cell cycle as well as normal growth and tumor suppression. BTG2 is not present in breast cancer. This protein is essential for protecting human mammary epithelial cells from oxidative stress. To trigger its function it requires the antioxidant transcription factor NFE2L2.

The Anti-NFE2L2 Marker antibody by Boster Bio is high affinity, which is a low molecular weight polyclonal form and is available in 10mM PBS with 0.05 percent BSA. The antibody is available in the form of a blocking peptide that is 1.0 mg/ml. It is also purchased separately, but cost is dependent on length of immunogen.

The antibody is prepared by using a lysate of a human cell lysate. To determine the NFE2L2 level, Western blotting is used. Each vial includes the immunogen as a soluble protein. The antibody is then applied to cells, and then detected using Western Blotting. The results are immediately available. Once you've obtained the Anti-NFE2L2 marker from Boster Bio, it is time to start your studies.

In a different study, BTG2 and NFE2L2 physically connect. A RNA-seq study revealed that NFE2L2 colocalizes with both ARE sites in their target genes. BTG2-BTG2 was co-precipitated by MCF-7 cells. These results indicate that NFE2L2 and BTG2 are functionally identical.

In mice, Nrf2 signaling pathway regulates DC maturation and migration. Mice without Nrf2 signaling have a higher percentage of activated T helper cells, but fewer regulatory cells than DCs that have it. The activation of DCs through Nrf2 signaling is beneficial to reduce disease severity and T cells infiltration. Activation of DCs is necessary in order to ensure that antigens are effectively delivered to T cells.

The antioxidant transcription factor Nrf2 regulates the maturation and differentiation of DCs. It also inhibits the production of reactive oxygen species and proinflammatory cytokines' expression. A deficiency in Nrf2 function is linked with neurodegenerative, autoimmune, and inflammation-related diseases. This is why the Anti-NFE2L2 marker in Boster Bio is an ideal antibody to detect the protein in osteoporosis in humans.

Cancerous cells have been identified to be affluent with mutations in nuclear factor erythroid 2like 2. This antibody binds with these mutants to stop cancer cell growth. In addition, it hinders the activity and activity of oxidative enzymes that are present in cells. These studies have proven that this treatment could reduce the effects of oxidative stress on cardiac function. The therapeutic benefits of this treatment are unsurpassed by other treatments that are on the market today.